Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jgs.17357 http://scihub22266oqcxt.onion/10.1111/jgs.17357 34235720!8447356!34235720     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Geriatr+Soc 2021 ; 69 (10): 2752-2758 Nephropedia Template TP {{tp|p=34235720|t=2021. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia |pdf=|usr=}}{{34235720}} gab.com Text Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia JO: J Am Geriatr Soc http://www.kidney.de/pget.php?&tw=1&pmid=34235720 #FOAvip BACKGROUND: Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia. METHODS: This is a propensity score [PS]-matched retrospective cohort study. Patients from the COVID-AGE and Alba-Score cohorts, hospitalized for moderate-to-severe COVID-19 pneumonia, were categorized in two age brackets of age <70 years old (86 with baricitinib and 86 PS-matched controls) or >/=70 years old (78 on baricitinib and 78 PS-matched controls). Thirty-day mortality rates were analyzed with Kaplan-Meier and Cox proportional hazard models. RESULTS: Mean age was 79.1 for those >/=70 years and 58.9 for those <70. Exactly 29.6% were female. Treatment with baricitinib resulted in a significant reduction in death from any cause by 48% in patients aged 70 or older, an 18.5% reduction in 30-day absolute mortality risk (n/N: 16/78 [20.5%] baricitinib, 30/78 [38.5%] in PS-matched controls, p < 0.001) and a lower 30-day adjusted fatality rate (HR 0.21; 95% CI 0.09-0.47; p < 0.001). Beneficial effects on mortality were also observed in the age group <70 (8.1% reduction in 30-day absolute mortality risk; HR 0.14; 95% CI 0.03-0.64; p = 0.011). CONCLUSIONS: Baricitinib is associated with an absolute mortality risk reduction of 18.5% in adults older than 70 years hospitalized with COVID-19 pneumonia. Twit Text FOAVip Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia ????J Am Geriatr Soc http://www.kidney.de/pget.php?&tw=1&pmid=34235720 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34235720 #FOAvip English Wikipedia <ref>{{Cite pmid|34235720}}</ref> Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia #MMPMID34235720 Abizanda P; Calbo Mayo JM; Mas Romero M; Cortes Zamora EB; Tabernero Sahuquillo MT; Romero Rizos L; Sanchez-Jurado PM; Sanchez-Nievas G; Campayo Escolano C; Ochoa Serrano A; Sanchez-Flor Alfaro V; Lopez Bru R; Gomez Ballesteros C; Caldevilla Bernardo D; Callejas Gonzalez FJ; Andres-Pretel F; Lauschke VM; Stebbing J J Am Geriatr Soc 2021[Oct]; 69 (10): 2752-2758 PMID34235720show ga BACKGROUND: Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia. METHODS: This is a propensity score [PS]-matched retrospective cohort study. Patients from the COVID-AGE and Alba-Score cohorts, hospitalized for moderate-to-severe COVID-19 pneumonia, were categorized in two age brackets of age <70 years old (86 with baricitinib and 86 PS-matched controls) or >/=70 years old (78 on baricitinib and 78 PS-matched controls). Thirty-day mortality rates were analyzed with Kaplan-Meier and Cox proportional hazard models. RESULTS: Mean age was 79.1 for those >/=70 years and 58.9 for those <70. Exactly 29.6% were female. Treatment with baricitinib resulted in a significant reduction in death from any cause by 48% in patients aged 70 or older, an 18.5% reduction in 30-day absolute mortality risk (n/N: 16/78 [20.5%] baricitinib, 30/78 [38.5%] in PS-matched controls, p < 0.001) and a lower 30-day adjusted fatality rate (HR 0.21; 95% CI 0.09-0.47; p < 0.001). Beneficial effects on mortality were also observed in the age group <70 (8.1% reduction in 30-day absolute mortality risk; HR 0.14; 95% CI 0.03-0.64; p = 0.011). CONCLUSIONS: Baricitinib is associated with an absolute mortality risk reduction of 18.5% in adults older than 70 years hospitalized with COVID-19 pneumonia. |*Azetidines/administration & dosage/adverse effects[MESH] |*COVID-19 Drug Treatment[MESH] |*COVID-19/mortality/physiopathology[MESH] |*Pneumonia, Viral/diagnosis/drug therapy[MESH] |*Purines/administration & dosage/adverse effects[MESH] |*Pyrazoles/administration & dosage/adverse effects[MESH] |*Sulfonamides/administration & dosage/adverse effects[MESH] |Age Factors[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antiviral Agents/administration & dosage/adverse effects[MESH] |Female[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Janus Kinase Inhibitors/administration & dosage/adverse effects[MESH] |Male[MESH] |Mortality[MESH] |Outcome and Process Assessment, Health Care[MESH] |SARS-CoV-2/isolation & purification[MESH] |Severity of Illness Index[MESH]Baricitinib reduces 30-day mortality in older adults with moderate-to-(epmc).pdf DeepDyve Pubget Overpricing